{"id":594482,"date":"2022-04-04T18:56:01","date_gmt":"2022-04-04T18:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=594482"},"modified":"2022-04-04T18:56:01","modified_gmt":"2022-04-04T18:56:01","slug":"companion-diagnostics-market-size-share-growth-emerging-trends-top-10-players-and-industry-outlook","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/companion-diagnostics-market-size-share-growth-emerging-trends-top-10-players-and-industry-outlook_594482.html","title":{"rendered":"Companion Diagnostics Market Size, Share, Growth, Emerging Trends, Top 10 Players and Industry Outlook"},"content":{"rendered":"
\n
\"Companion<\/a><\/div>\n
\n
Key Players in Companion Diagnostics Market F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioM\u00e9rieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan).<\/div>\n<\/div>\n<\/div>\n
Companion Diagnostics Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size.<\/div>\n

According to the new market research report “Companion Diagnostics Market<\/a> by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region – Global Forecast to 2026<\/strong>“, published by MarketsandMarkets™, the global Companion Diagnostics Market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6%.<\/p>\n

Opportunity: Increasing demand for next-generation sequencing<\/strong><\/p>\n

NGS-based companion diagnostic tests aim to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of many different types of cancers. The various technological advancements in NGS also provide market players with an immediate competitive edge over players providing other technologies such as PCR, ICH, and ISH. As a result, major market players are focusing on developing companion diagnostic products based on NGS.<\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=155571681<\/a><\/p>\n

The policy programs to provide effective care to patients with cancer, high drug development activity, structured regulatory framework in the region, and large patient pool undergoing advanced medical testing. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the companion diagnostics market.<\/p>\n

The assays, kits & reagents segment accounted for the largest share of the companion diagnostics market, by product & service segment, in 2020<\/strong><\/p>\n

The companion diagnostics market is segmented into assays, kits & reagents, and software & services. The assays, kits & reagents accounted for the largest share of the companion diagnostics market in 2020, mainly due to the availability of a wide range of products and increasing use of assays and kits in different therapeutic areas.<\/p>\n

PCR segment to register the highest growth rate during the forecast period<\/strong><\/p>\n

The companion diagnostics market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies. In 2020, the PCR segment accounted for the largest share of the companion diagnostics market. Factors such as the ease of use and widespread availability of PCR kits & reagents in companion diagnostic testing, and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=155571681<\/a><\/p>\n

Cancer segment to register the highest growth rate during the forecast period<\/strong><\/p>\n

The companion diagnostics market is segmented into cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications (inflammatory and inherited diseases, among others). In 2020, the cancer segment accounted for the largest share of the companion diagnostics market. Factors such as growing role of companion diagnostics in the personalized medicine treatment for cancer, and increasing utility of biomarkers in the diagnosis of cancer.<\/p>\n

The pharmaceutical & biotechnology companies segment accounted for the largest share of the companion diagnostics market, by end user segment, in 2020<\/strong><\/p>\n

Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users (including physician & hospital laboratories, and academic medical centers). In 2020, pharmaceutical & biotechnology companies accounted for a larger share of the companion diagnostics market. The growing use of companion diagnostics owing to their increasing prominence in drug development, and the increasing importance of companion diagnostic biomarkers.<\/p>\n

Speak to Analyst: <\/strong>https:\/\/www.marketsandmarkets.com\/speaktoanalystNew.asp?id=155571681<\/a><\/p>\n

North America is the largest regional market for companion diagnostics market<\/strong><\/p>\n

The global companion diagnostics market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the companion diagnostics market. The North American companion diagnostics market growth can be attributed to the presence of many leading companion diagnostics vendors & national clinical laboratories, the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.<\/p>\n

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/companion-diagnostics-market-155571681.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Key Players in Companion Diagnostics Market F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioM\u00e9rieux SA (France), Myriad … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,406,403,404],"tags":[],"class_list":["post-594482","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/594482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=594482"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/594482\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=594482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=594482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=594482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}